首页> 美国卫生研究院文献>Stem Cells and Development >Improved Mobilization of the CD34+ and CD133+ Bone Marrow-Derived Circulating Progenitor Cells by Freshly Isolated Intracoronary Bone Marrow Cell Transplantation in Patients with Ischemic Heart Disease
【2h】

Improved Mobilization of the CD34+ and CD133+ Bone Marrow-Derived Circulating Progenitor Cells by Freshly Isolated Intracoronary Bone Marrow Cell Transplantation in Patients with Ischemic Heart Disease

机译:新鲜分离的冠状动脉内骨髓细胞移植治疗缺血性心脏病患者提高了CD34 +和CD133 +骨髓循环祖细胞的动员能力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cell therapy is a promising novel option for treatment of cardiovascular disease. Because the role of bone marrow-derived circulating progenitor cells (BM-CPCs) after cell therapy is less clear, we analyzed in this randomized, controlled study the influence of intracoronary autologous freshly isolated bone marrow cell transplantation (BMC-Tx) by using a point-of-care system on cardiac function and on the mobilization of BM-CPCs in patients with ischemic heart disease (IHD). Fifty-six patients with IHD were randomized to either receive freshly isolated BMC-Tx or a control group that did not receive cell therapy. Peripheral blood concentrations of CD34/45+ and CD133/45+ CPCs were measured by flow cytometry pre-, immediately post-, and at 3, 6, and 12 months postprocedure in both groups. Global ejection fraction and the size of infarct area were determined by left ventriculography. We observed in patients with IHD after intracoronary transplantation of autologous freshly isolated BMCs-Tx at 3 and 12 months follow-up a significant reduction of the size of infarct area and increase of global ejection fraction as well as infarct wall movement velocity. The mobilization of CD34/45+ and CD133/45+ BM-CPCs significantly increased at 3, 6, and 12 months after cell therapy when compared with baseline in patients with IHD, although no significant changes were observed between pre- and immediately postintracoronary cell therapy administration. In the control group without cell therapy, there was no significant difference of CD34/45+ and CD133/45+ BM-CPCs mobilization between pre- and at 3, 6, and 12 months postcoronary angiography. Intracoronary transplantation of autologous freshly isolated BMCs by using a point-of-care system in patients with IHD may enhance and prolong the mobilization of CD34/45+ and CD133/45+ BM-CPCs in peripheral blood and this might increase the regenerative potency in IHD.
机译:细胞疗法是治疗心血管疾病的有希望的新选择。由于细胞治疗后骨髓源性循环祖细胞(BM-CPC)的作用尚不清楚,因此我们在这项随机对照研究中分析了冠状动脉内自体新鲜分离的骨髓细胞移植(BMC-Tx)的影响,方法是使用缺血性心脏病(IHD)患者心脏功能和动员BM-CPC的即时医疗系统。 56例IHD患者被随机分配接受新鲜分离的BMC-Tx或未接受细胞治疗的对照组。术前,术后及术后3、6和12个月通过流式细胞仪测量CD34 / 45 + 和CD133 / 45 + CPC的外周血浓度在两组中。通过左心室造影确定总体射血分数和梗塞区域的大小。我们观察到,在IHD患者中,在3个月和12个月的随访中进行了自体新鲜分离的BMCs-Tx的冠状动脉内移植后,梗死区域的大小显着减少,总射血分数以及梗死壁运动速度明显增加。与IHD患者相比,细胞治疗后3、6和12个月时CD34 / 45 + 和CD133 / 45 + BM-CPC的动员显着增加,尽管在冠状动脉内细胞治疗前后之间没有观察到明显变化。在未进行细胞治疗的对照组中,CD34 / 45 + 和CD133 / 45 + BM-CPC的动员时间在术前和术后3、6之间没有显着差异。冠状动脉造影后12个月。在IHD患者中使用即时护理系统进行自体新鲜分离的BMC的冠状动脉内移植可增强和延长CD34 / 45 + 和CD133 / 45 + 的动员外周血中的BM-CPCs可能会增加IHD的再生能力。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号